

**HEXTAR HEALTHCARE BERHAD (199601000297) (372642-U)**

Condensed Consolidated Statements of Comprehensive Income for the first quarter ended 31 March 2026  
These figures have not been audited

	<b>Individual Period</b>		<b>Cumulative Period</b>	
	2026 Current Year Quarter ended 31 March RM'000	2025 Preceding Year Quarter ended 31 March RM'000	2026 Current Year to-Date ended 31 March RM'000	2025 Preceding Year to-Date ended 31 March RM'000
Revenue	31,049	37,626	31,049	37,626
Cost of sales	(30,238)	(38,313)	(30,238)	(38,313)
<b>Gross Profit/(Loss)</b>	<b>811</b>	<b>(687)</b>	<b>811</b>	<b>(687)</b>
Other gains and losses	(238)	133	(238)	133
Operating expenses	(3,267)	(3,263)	(3,267)	(3,263)
<b>(Loss) from operations</b>	<b>(2,694)</b>	<b>(3,817)</b>	<b>(2,694)</b>	<b>(3,817)</b>
Finance costs	(22)	(85)	(22)	(85)
Share of losses in an associate	-	(208)	-	(208)
<b>(Loss) before tax</b>	<b>(2,716)</b>	<b>(4,110)</b>	<b>(2,716)</b>	<b>(4,110)</b>
Income tax (expense)/credit	(211)	611	(211)	611
<b>(LOSS) FOR THE PERIOD ATTRIBUTABLE TO EQUITY HOLDERS OF THE COMPANY</b>	<b>(2,927)</b>	<b>(3,499)</b>	<b>(2,927)</b>	<b>(3,499)</b>
<b>Other comprehensive income, net of tax:</b>				
Foreign currency translation differences for foreign operations	(559)	467	(559)	467
<b>Total comprehensive (loss) for the period attributable to Equity holders of the Company</b>	<b>(3,486)</b>	<b>(3,032)</b>	<b>(3,486)</b>	<b>(3,032)</b>
<b>(Loss) per share:</b>				
Basic (sen)	(0.27)	(0.32)	(0.27)	(0.32)
Weighted average number of shares	1,102,110,781	1,102,110,781	1,102,110,781	1,102,110,781

*The condensed consolidated statements of comprehensive income should be read in conjunction with the audited financial statements for the year ended 31 December 2025 and the accompanying notes attached to the interim financial statements.*

**HEXTAR HEALTHCARE BERHAD (199601000297) (372642-U)**

Condensed Consolidated Statements of Financial Position as of 31 March 2026  
These figures have not been audited

	As of 31 March 2026 RM'000	As of 31 December 2025 RM'000
<b>ASSETS</b>		
<b>Non-current Assets</b>		
Property, plant and equipment	165,208	167,490
Prepaid lease payments	4,421	4,440
Deferred tax asset	5,548	5,817
Other investments	165,094	165,094
Right-of-use assets	3,642	2,200
	<u>343,913</u>	<u>345,041</u>
<b>Current Assets</b>		
Inventories	43,709	44,363
Trade receivables	14,302	20,121
Other receivables	40,055	44,406
Other investments	1,033	1,025
Cash and bank balances	30,834	22,847
	<u>129,933</u>	<u>132,762</u>
<b>TOTAL ASSETS</b>	<u><b>473,846</b></u>	<u><b>477,803</b></u>
<b>EQUITY AND LIABILITIES</b>		
<b>Equity attributable to equity holders of the Company</b>		
Issued capital	361,387	361,387
Treasury shares	(48,191)	(48,191)
Other reserves	(49,793)	(49,234)
Retained earnings	185,562	188,489
<b>TOTAL EQUITY</b>	<u>448,965</u>	<u>452,451</u>
<b>Non-current Liabilities</b>		
Borrowings	7	10
Lease liabilities	457	457
Deferred tax liabilities	1,994	2,079
	<u>2,458</u>	<u>2,546</u>
<b>Current Liabilities</b>		
Trade payables	7,318	8,420
Other payables	11,837	12,546
Lease liabilities	3,225	1,779
Borrowings	43	61
	<u>22,423</u>	<u>22,806</u>
<b>TOTAL LIABILITIES</b>	<u>24,881</u>	<u>25,352</u>
<b>TOTAL EQUITY AND LIABILITIES</b>	<u><b>473,846</b></u>	<u><b>477,803</b></u>
Net asset per share (RM)	0.42	0.41

*The condensed consolidated statements of financial position should be read in conjunction with the audited financial statements for the year ended 31 December 2025 and the accompanying notes attached to the interim financial statements.*



**HEXTAR HEALTHCARE BERHAD (199601000297) (372642-U)**

Condensed Consolidated Statements of Changes in Equity for the first quarter ended 31 March 2026  
 These figures have not been audited

	Attributable to Equity Holders of the Company						Total Equity RM'000
	Share Capital RM'000	Treasury Shares RM'000	Revaluation Reserves RM'000	Fair Value Reserves RM'000	Translation Reserves RM'000	Retained Earnings RM'000	
<b>As at 01 January 2025</b>	361,387	(48,191)	413	(38,648)	119	232,990	508,070
Total comprehensive (loss) for the period	-	-	-	-	-	(3,499)	(3,499)
Effects of foreign exchange differences	-	-	-	-	467	-	467
<b>As at 31 March 2025</b>	<u>361,387</u>	<u>(48,191)</u>	<u>413</u>	<u>(38,648)</u>	<u>586</u>	<u>229,491</u>	<u>505,038</u>
<b>As at 01 January 2026</b>	361,387	(48,191)	184	(49,975)	557	188,489	452,451
Total comprehensive (loss) for the period	-	-	-	-	-	(2,927)	(2,927)
Effects of foreign exchange differences	-	-	-	-	(559)	-	(559)
<b>As at 31 March 2026</b>	<u>361,387</u>	<u>(48,191)</u>	<u>184</u>	<u>(49,975)</u>	<u>(2)</u>	<u>185,562</u>	<u>448,965</u>

*The condensed consolidated statements of changes in equity should be read in conjunction with the audited financial statements for the year ended 31 December 2025 and the accompanying notes attached to the interim financial statements.*

**HEXTAR HEALTHCARE BERHAD (199601000297) (372642-U)**

Condensed Consolidated Statements of Cashflows for the first quarter ended 31 March 2026

These figures have not been audited

	2026 Year ended 31 March RM'000	2025 Year ended 31 December RM'000
(Loss) before tax	(2,716)	(35,457)
Adjustments for non-cash flow items	3,604	33,495
Operating profit/(loss) before changes in working capital	<u>888</u>	<u>(1,962)</u>
(Increase)/Decrease in current assets:		
Inventories	694	16,172
Trade and other receivables	8,532	(218)
Decrease in current liabilities:		
Trade and other payables	<u>(1,803)</u>	<u>(4,191)</u>
Cash from operations	<u>8,311</u>	<u>9,801</u>
Net income tax refunded	<u>1,218</u>	<u>9,156</u>
<b>Nett cashflows from operating activities</b>	<b><u>9,529</u></b>	<b><u>18,957</u></b>
Cashflows from/(used in) investing activities:		
Advances to an associate	-	(7,103)
Purchase of property, plant and equipment	(815)	(6,512)
Proceeds from disposal of property, plant and equipment	-	11,969
Addition of other investment	-	(1,024)
Interests received	<u>168</u>	<u>131</u>
<b>Nett cashflows used in investing activities</b>	<b><u>(647)</u></b>	<b><u>(2,539)</u></b>
Cashflows from/(used in) financing activities:		
(Repayment)/Drawdown of bills payable	-	-
Repayment of term loan and hire purchase payables	(20)	(716)
Interests on borrowings paid	(1)	(556)
Repayment of lease liabilities	<u>(466)</u>	<u>(1,712)</u>
<b>Nett cashflows used in financing activities</b>	<b><u>(487)</u></b>	<b><u>(2,984)</u></b>
Net increase in cash and cash equivalents	8,395	13,434
Cash and cash equivalents at beginning of financial period	22,414	8,797
Effect of foreign exchange differences	<u>(408)</u>	<u>183</u>
Cash and cash equivalents at end of financial period	<b><u>30,401</u></b>	<b><u>22,414</u></b>
Cash and cash equivalents at end of financial period comprise the following:		
Cash and bank balances	30,834	22,847
Less: Fixed deposits pledged to bank	<u>(433)</u>	<u>(433)</u>
	<b><u>30,401</u></b>	<b><u>22,414</u></b>

*The condensed consolidated statements of cashflows should be read in conjunction with the audited financial statements for the year ended 31 December 2025 and the accompanying notes attached to the interim financial statements.*



## NOTES TO THE INTERIM FINANCIAL REPORT FOR THE FIRST QUARTER ENDED 31 MARCH 2026

### A. EXPLANATORY NOTES PURSUANT TO MALAYSIAN FINANCIAL REPORTING STANDARD (“MFRS”) 134: INTERIM FINANCIAL REPORTING

#### 1. Basis of Preparation of the Financial Statements and Adoption of New and Revised Malaysian Financial Reporting Standards (“MFRSs”)

The interim financial report is unaudited and has been prepared in accordance with Malaysian Financial Reporting Standard (MFRS) 134: Interim Financial Reporting and paragraph 9.22 of the Listing Requirements of Bursa Malaysia Securities Berhad and should be read in conjunction with the audited financial statements of the Group for the financial year ended 31 December 2025.

The accounting policies and methods of computation adopted for the interim financial statements were consistent with those adopted for the annual audited financial statements for the year ended 31 December 2025.

#### 2. Auditor’s Report on Preceding Annual Financial Statements

The auditor’s report on the financial statements of the Group and the Company for the previous year ended 31 December 2025 was not subject to any qualification.

#### 3. Seasonal or Cyclical Factors

The Group’s products are not materially impacted by any seasonal or cyclical factors.

#### 4. Unusual Items due to their Nature, Size or Incidence

There were no unusual items affecting the Group’s assets, liabilities, equity, net income or cash flows in the financial statements for the period ended 31 March 2026.

#### 5. Changes in Material Estimates

There were no changes in the nature and computation of estimates reported in prior financial year(s) that have a material effect in the financial statements for the period ended 31 March 2026.

#### 6. Changes in Debt and Equity Securities

##### 6.1 Share Buy-back

The Company did not carry out any Share Buy-back in the current financial year.

As of 31 March 2026, a total of 91,273,100 shares were held as Treasury Shares by the Company, and the net number of issued shares was 1,102,110,781 shares.

#### 7. Dividends Paid

No dividends have been declared by the Company in respect of the current financial year.



## 8. Segmental Information

Segmental information is presented in accordance to business operating activities, which is the Group's primary reporting format.

	Gloves Operation RM'000	Medical Devices Operation RM'000	Property Investment RM'000	Current quarter ended 31 March 2026 RM'000	Cumulative year-to-date RM'000
Revenue	30,183	866	-	31,049	31,049
Segment Results	(2,662)	(193)	-	(2,855)	(2,855)
Investment Income	153	8	-	161	161
Finance Costs	-	(22)	-	(22)	(22)
(Loss) before Tax	(2,509)	(207)	-	(2,716)	(2,716)
Tax Expense	(211)	-	-	(211)	(211)
(Loss) after Tax	<b>(2,720)</b>	<b>(207)</b>	-	<b>(2,927)</b>	<b>(2,927)</b>

## 9. Valuation of Property, Plant and Equipment

The Group did not carry out any revaluations on its property, plant and equipment in the current quarter ended 31 March 2026.

The values of property, plant and equipment have been brought forward without amendment from the previous annual financial statements as of 31 December 2025.

## 10. Subsequent Events

There were no events subsequent to the end of the current quarter that have not been reflected in the financial period ended 31 March 2026.

## 11. Changes in the Composition of the Group

Save for the allotment of 6,600 new ordinary shares in an associated company, Alliance Empire Sdn Bhd in January 2026, resulting in a dilution of shareholding from 20.0% to 19.9% in the Company's wholly-owned subsidiary, Rubberex Empire Sdn Bhd, due to the non-participation in additional capital funding, there were no changes to the composition of the Group including business combinations, acquisition or disposal of subsidiaries and long-term investments, restructuring and discontinuing operations since the last audited financial year ended 31 December 2025.

## 12. Changes in Contingent Liabilities or Contingent Assets

There were no changes in contingent liabilities or assets since the last audited annual balance sheet date of 31 December 2025.

## 13. Capital Commitments

There was no commitment for the purchase of property, plant and equipment not provided for in the financial statements for the period ended 31 March 2026.

**B. ADDITIONAL INFORMATION PURSUANT TO APPENDIX 9B OF THE LISTING REQUIREMENTS OF BURSA MALAYSIA SECURITIES BERHAD****1. Review of Performance**

The Group recorded a revenue of RM31.0 million in the current quarter compared to RM37.6 million in the corresponding quarter ended 31 March 2025, a decrease of RM6.6 million or 17.5%. Loss after tax in the current quarter amounted to RM2.9 million compared to RM3.5 million in the corresponding period of the previous year, driven by the lower sales revenue and higher operating costs due to the low capacity utilization of its plants in the current quarter compared to the corresponding period of the previous financial year.

**2. Material change in profits of the current quarter compared with preceding quarter**

The Group recorded a loss after tax in the current first quarter of RM2.9 million, compared to RM19.2 million in the preceding fourth quarter of previous financial year 2025, a decrease of RM16.3 million, mainly attributable to the impairment loss on investment as well as deferred tax adjustments taken up in the preceding quarter.

**3. Current Year Prospects**

The Group's glove and medical devices businesses are expected to remain challenging in the short to medium term, amidst global trade uncertainties, foreign exchange risks and rising material prices, energy and labour costs. However, the Group remains committed to its core businesses and is focused on driving revenue, increasing operational efficiency and maintaining effective cost controls at its key operational divisions for financial year 2026.

**4. Profit Forecast or Profit Guarantee**

No profit forecast or profit guarantee has been issued for the current quarter.

**5. Taxation expense**

	Current quarter ended 31 March 2026 RM'000	Cumulative year- to-date RM'000
Current year – Malaysian income tax	63	63
Current year – Foreign income tax	102	102
Deferred tax	46	46
Total income tax expense	<b>211</b>	<b>211</b>

**6. Sales of Unquoted Investments and/or Properties**

There were no sales of unquoted investments and/or properties in the current quarter ended 31 March 2026.

**7. Purchase/disposal of Quoted Securities**

There were no purchase and/or disposal of quoted securities for the current quarter ended 31 March 2026.

**8. Status of Corporate Proposals**

There were no corporate proposals not announced or outstanding as of 31 March 2026.

**9. Group Borrowings and Debt Securities**

	As of 31 March 2026		
	Secured RM'000	Unsecured RM'000	Total RM'000
Current	-	43	43
Non-current	-	7	7
	<b>-</b>	<b>50</b>	<b>50</b>

**10. Financial Instruments Risks**

As of 31 December 2026, the Group has the following foreign currency contracts outstanding: -

	Contracted Amount '000	Ringgit Equivalent RM'000	Fair Value RM'000
U.S. Dollar (USD)	1,158	4,576	4,687
Euro (EUR)	139	641	647
Swiss Franc (CHF)	50	253	253
		<b>5,470</b>	<b>5,587</b>

The above foreign currency contracts were entered into with local licensed banks to hedge the Group's receivables and payables in foreign currencies. The contracted rates will be used to translate the underlying foreign currencies into Ringgit Malaysia.

These foreign currency contracts are of a short-term nature. The accounting policy adopted with regards to off balance sheet financial instruments was consistent with those applied in the last audited financial statements as of 31 December 2025.

**11. Changes in Material Litigation**

There was no outstanding material litigation as of 31 March 2026.

**12. Dividend Payable**

No dividend is proposed for the current quarter ended 31 March 2026.

**13. (Loss) per Share**

		Cumulative Year-to-Date ended 31 March 2026	Cumulative Year-to-Date ended 31 March 2025
(Loss) for the period attributable to equity holders of the Company	RM'000	(2,927)	(3,499)
Weighted average number of ordinary shares in issue	Shares	1,102,110,781	1,102,110,781
<b>(Loss) per share</b>	<b>sen</b>	<b>(0.27)</b>	<b>(0.32)</b>



**14. Authorisation for Issue**

The interim financial statements and explanatory notes were authorised for issue by the Board of Directors on 22 May 2026.